"Asymptomatic" Malaria: A Chronic and Debilitating Infection That Should Be Treated.

Chen I, Clarke SE, Gosling R, Hamainza B, Killeen G, Magill A, O'Meara W, Price RN, Riley EM. · 2016

Read "Asymptomatic" Malaria: A Chronic and Debilitating Infection That Should Be Treated. by Chen I, Clarke SE, Gosling R, Hamainza B, Killeen G, Magill A, O'Meara W, Price RN, Riley EM. (2016) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc4718522.txt.

Introduction

Ingrid Chen, Siân E. Clarke, Roly Gosling, and six colleagues argued that symptom-free malaria is neither harmless nor well named, in PLoS Medicine in 2016. Malaria infections without fever are usually called asymptomatic and sometimes even treated as useful, since they keep partial immunity topped up. The authors marshal evidence against that comfort. Such infections bring repeated bouts of illness, chronic anemia, risks to mothers and newborns, worse outcomes with bacterial infections, and harm to children's thinking.

They also keep the parasite circulating to new victims. The proposal is to rename these infections chronic malaria and to treat them as disease, not background. Finding and curing them is hard, involving scientific, practical, and ethical hurdles the authors list frankly. Still, they call on malaria programs to aim at every infection, whatever its density or symptoms. The gains, they argue, would reach both the infected person and the whole community.

Catalog record

CREATORChen I, Clarke SE, Gosling R, Hamainza B, Killeen G, Magill A, O'Meara W, Price RN, Riley EM.
YEAR2016
COLLECTIONPAPERS
FORMATTXT
FILE SIZE41 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC4718522

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

“Asymptomatic” Malaria: A Chronic and Debilitating Infection That Should Be Treated By Ingrid Chen, Siân E Clarke, Roly Gosling, Busiku Hamainza, Gerry Killeen, Alan Magill, Wendy O’Meara, Ric N Price, Eleanor M Riley Published in: PLoS Medicine DOI: 10.1371/journal.pmed.1001942 ABSTRACT Abstract Roland Gosling and colleagues argue that "asymptomatic" malaria infections have significant health and societal consequences, and propose that they should be renamed "chronic" malaria infections. Summary PointsAre afebrile malaria infections truly asymptomatic, benign, or even beneficial to the individual? The evidence suggests the contrary.So-called “asymptomatic” malaria infections are associated with recurrent episodes of symptomatic parasitemia, chronic anemia, maternal and neonatal mortality, co-infection with invasive bacterial disease, cognitive impairment, and ongoing transmission of the parasite.“Asymptomatic” malaria infections have significant health and societal consequences, and we propose that they should be renamed “chronic” malaria infections.Targeting chronic malaria infections poses major scientific, operational, and ethical challenges.We call for the malaria community to work with malaria control and elimination programs to target all malaria infections, irrespective of their density or presentation. The operational challenges to detect and treat chronic infections are significant, but accomplishing this is likely to result in substantial gains to both the individual and society. BACKGROUND Since ancient times, the concept of malaria has been synonymous with its most obvious symptoms: a characteristic recurrent cycle of fevers and chills. Obvious symptoms and severe disease mostly occur in partially immune or non-immune individuals, especially children in high-transmission settings and visitors to endemic areas. So-called “asymptomatic” malaria infections have been recognized for many years, and result from partial immunity (sometimes referred to as “premunition”), which controls but does not completely eliminate the infection. Thus, persistent or repeated “asymptomatic” infection is sometimes viewed as beneficial to the individual, as it helps to maintain this state of premunition, thereby reducing the risk of severe disease [1]. In this paper, we present evidence to the contrary: persistent infections with malaria parasites are frequently detrimental to the individual, with serious health, developmental, and productivity consequences. We propose they should be described more accurately as “chronic” infections requiring curative treatment. Although there is no standard definition for “asymptomatic” malaria infections, it is generally accepted to be malarial parasitemia of any density, in the absence of fever or other acute symptoms, in individuals who have not received recent antimalarial treatment [2]. At any given time, the vast majority of individuals with detectable malaria parasitemia can be categorized as asymptomatic based on this definition, regardless of the level of malaria transmission [3]. This definition includes early detection of rising parasitemia that has yet to reach the pyrogenic threshold (i.e., the density of parasitized erythrocytes that is sufficient to trigger innate immune responses and fever) [4], infections that are intermittently symptomatic but not severe enough to cause the person to seek health care [5], and long-standing infections imperfectly controlled by the immune response. Current guidelines aim to improve the early detection of new symptomatic and subacute cases, for example, through the use of village health workers [6], but this strategy does not reach individuals carrying low-density, chronic infections. Chronic infections tend to be of substantially lower density than acutely symptomatic infections; indeed, they can be “submicroscopic” (i.e., not detected on a blood film or by rapid diagnostic test [RDT] but detectable by more sensitive tests such as PCR) and can persist for several months or even years [4]. An important question is whether “asymptomatic” malaria infections are truly benign and, if not, whether the advantages of premunition are outweighed by the harm that arises from persistent blood-stage parasites. If so, are there particular high-risk groups, in addition to young children and pregnant women, which need to be identified? From a public health perspective, the risks and benefits need to be examined with regard not just to the individual’s well-being but also within the wider context of sustainable malaria control strategies that may lead to elimination and eradication. In this policy forum article, we propose that, notwithstanding the policy and programmatic challenges that will arise, treating all malaria infections, irrespective of their clinical presentation, will confer direct clinical benefits to the individual and may contribute to improved malaria control at the population level by reducing onward transmission. This paper is a collection of four strands of evidence supporting our argument: that malaria infections of any density are important to find and to treat. EVIDENCE Malaria Control Interventions Reduce All-Cause Morbidity and Mortality It has long been suspected that infection with malaria parasites at any density of infection may exacerbate other diseases, and, thus, reducing the prevalence of malaria will reduce mortality and morbidity ascribed to other causes. At an individual level, the relationship between parasitemia, morbidity, and mortality is complicated by the fact that while malaria infection can be the primary causal agent, it can also be a contributing co-morbidity, or it can be coincidental and unrelated to the main cause of illness. At a population level, changes in all-cause, rather than malaria-specific, morbidity and mortality under effective control strategies offer insight into the contribution of malaria as an indirect cause of hospitalization, illness, and death. Observational evidence from Kilifi, Kenya, showed that there was an excess reduction in all-cause hospital admissions as malaria transmission in the area declined [7]. The reduction in all-cause hospital admissions was greater than that expected from the decline in malaria admissions alone based on estimation of the malaria-attributable fraction (the proportion of malaria episodes in which parasites are responsible for the fever, estimated by comparing parasite density in asymptomatic infections to parasite density in symptomatic cases). The decline in malaria episodes was accompanied by a concurrent decline in invasive bacterial disease [8], supporting the notion that malaria infection predisposes individuals to bacteremia (see below). Among malaria intervention trials that report all-cause mortality as an outcome, the reduction in overall mortality consistently exceeds that of malaria-specific mortality [9–12]. Two seminal insecticide treated bed-net (ITN) trials, one in The Gambia and one in Ghana, showed significant reductions in all-cause mortality of 20%–25% amongst children protected by ITNs but no significant differences in malaria-specific mortality [9,10]. Similarly, a chemoprophylaxis study in The Gambia demonstrated marked reductions in all-cause mortality after just one year of chemoprotection [11]. The reduction in all-cause mortality was more than twice the reduction in malaria-specific mortality after one year and three to four years of protection [11,12]. These findings clearly implicate undiagnosed “asymptomatic” malaria infections as a component of some multifactorial causes of death. Impact on morbidity is more complex. The reduction in all illness episodes in infants receiving malaria chemoprophylaxis from birth was twice the reduction in malaria-specific outpatient events [13]. A chemoprophylaxis trial in children under five years of age also demonstrated a reduction in all-cause morbidity, including lower rates of gastrointestinal and respiratory illness, although the effect was only apparent after three to four years of chemoprotection and was less than the change in malaria-specific morbidity [12,14]. Conversely, a chemoprophylaxis study in schoolchildren in a region of moderate to high malaria endemicity demonstrated no reduction in all-cause hospitalization after accounting for reductions in malaria episodes [15]. Taken together, the impact of reducing malaria infection on other causes of morbidity may be most apparent in non-immune populations (i.e., in infants or in

Read the complete text